Podcasts about wolchok

This episode of “From Bench to Fireside” is a special one for PICI that marks a network expansion with Weill Cornell Medicine joining as our newest PICI Center. The partnership will build upon PICI's work to accelerate research efforts in cancer immunotherapy and represents an expansion for PICI on the East Coast. Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and newly appointed Director for the PICI Center at Weill Cornell Medicine, talks with PICI Chief Scientific Officer John Connolly, PhD, to discuss the new cancer immuno-oncology research center in NYC.Dr. Wolchok, who previously served as PICI Center Director at Memorial Sloan Kettering Cancer Center (MSKCC), shares his vision for the PICI Center at Weill Cornell, ideas for integrating clinical research and cancer care to improve access for diverse populations, ambitions to accelerate cancer immunotherapy research, and a two-decade exploration of the immune system's interaction with cancer. He also dives into challenges targeting checkpoint inhibitors, advancements in manufacturing cell therapies, personalized cancer vaccines, and the potential of engineered cytokines in next-gen immunotherapies.Get ready to go from bench to fireside with Dr. Jedd Wolchok as he shares his bold vision for the future of the field.++From Bench to Fireside™ is a podcast from the Parker Institute for Cancer Immunotherapy (PICI) that takes you from behind the lab bench to the frontiers of cancer research. Each episode features an interview with members of the PICI Network, pioneers in cancer immunotherapy and leaders at world-renowned cancer research institutions. Throughout the conversations, these experts weigh in on the potential of the human immune system to target and eradicate cancer cells, from the latest breakthroughs in immuno-oncology to their impact on patients. Along the way, they unpack the hurdles encountered and the opportunities that lie ahead.Tune in to hear from scientific leaders who stand at the forefront of developing breakthrough immune therapies with the goal of turning all cancers into curable diseases.From Bench to Fireside™ is produced by the Parker Institute for Cancer Immunotherapy. Follow PICI on ⁠LinkedIn⁠, X ⁠@parkerici⁠ or visit ⁠www.parkerici.org⁠.

Judy Blume is alive and well.  While no longer writing books, at 85 she still bikes around the lively streets of Key West, stopping in to tend the book shop she bought a few years ago.  And she serves as the vivacious, charismatic center of “Judy Blume Forever”.   Directors Davina Pardo and Leah Wolchok sat down with Mike Merrill to discuss how their film centers Blume both within a coterie of authors she influenced as well as within the shifting cultural landscape of the key years that she was writing–the 1970s–that are still resonating in our world today.     Judy Blume forever is now streaming on Amazon Prime.   Hidden Gems: Missing Allen Smoke Sauna Sisterhood   Follow: @davinapardo on twitter @judyblume on twitter and @judyblume4real on instagram @topdocspod on Instagram and twitter   The Presenting Sponsor of "Top Docs" is Netflix.

Q&A on the documentary Judy Blume Forever with directors & producers Davina Pardo and Leah Wolchok. Moderated by Mara Webster, In Creative Company. Trailblazing author Judy Blume's radical honesty changed the way millions of adolescent readers understood themselves, their sexuality, and what it meant to grow up.

Vegas Film Critic (Jeffrey K. Howard) speaks with Davina Pardo and Leah Wolchok for Judy Blume Forever on Prime Video. 

Judy Blume Forever explores the life and legacy of trailblazing author Judy Blume, whose honest and captivating books changed the way millions of adolescent readers understood themselves and what it meant to grow up. In this special episode, Zibby interviews Judy (again!?!) and the film's directors. Zibby and Judy talk about their bookstores, giving love another chance, and fan mail (Judy has kept every single letter she has ever received!). Then, the directors share what it was like to work on this special project. Now there's more! Subscribe to Moms Don't Have Time to Read Books on Acast+ and get ad-free episodes or exclusive access to the in-store author events at Zibby's Bookshop in Santa Monica, CA. Join today! https://plus.acast.com/s/moms-dont-have-time-to-read-books. Hosted on Acast. See acast.com/privacy for more information.

Alison and Jody take a break from Rachel Robinson to hang with the directors/producers of Judy Blume Forever, Davina Pardo and Leah Wolchok! Listen in for an intimate Blume Head chat about the absolutely phenomenal documentary and a li'l recap of the film, out now on Amazon Prime! Thank you Davina and Leah for spending time in the Cocoon with us, what a TREAT!

Unless you've been living under a rock you know the author Judy Blume. Now streaming on Amazon Prime is Judy Blume Forever, a documentary that takes readers inside the life of Blume and her incredible works. We had the chance to sit down for an interview with director Leah Wolchok to learn more about the … Continue reading "S4E6: Interview With Director Leah Wolchok" The post S4E6: Interview With Director Leah Wolchok appeared first on Geek Girls Universe.

Melissa interviews the directors of the new documentary Judy Blume Forever, Davina Pardo and Leah Wolchok, which premieres on Amazon Prime on April 21st. She also talks to Hannah Bos, one of the co-creators of Somebody Somewhere, which returns for its second season on HBO on April 23rd. Show Notes: Judy Blume Forever Trailer ⁠Hannah Bos' Instagram Somebody Somewhere S2 Trailer In Her Voice is a Woman and Hollywood Podcast, hosted by Melissa Silverstein (Founder of ⁠Women and Hollywood⁠ and Co-Founder of the ⁠Athena Film Festival) and produced by ⁠⁠Leonie Marsh⁠⁠. Subscribe to this podcast on Spotify or wherever you listen to your podcasts. ⁠Join Substack ⁠for Melissa's weekly curated list of content made by women. Twitter ⁠@melsil⁠ and ⁠@womenahollywood⁠ Instagram ⁠@womenandhollywood

Really? Decadron can worsen mortality in GBMs? This week Karl and I go over the evidence showing that steroids might not be the best thing for GBM patients. Specifically, it looks like dexamethasone might interfere with the effectiveness of chemo and radiation, leading to worse outcomes. Literature Referenced: Opinion paper that summarizes the argument against using Decadron in GBM patients: Wong, E., Swanson, K. (2019). Dexamethasone—Friend or Foe for Patients With Glioblastoma? JAMA Neurology 76(3) https://dx.doi.org/10.1001/jamaneurol.2018.4530 Retrospective post-hoc comparison of Decadron dose in NovoTTF vs. best physician’s choice (BPC) chemo.Patients were dichotomized to > or < 4mg/day. Improved survival seen in low Decadron dose group. NovoTTF patients: median OS 4.8mo vs. 11.0mo, BPC chemo patients: 6.0mo vs. 8.9mo (effect seemed to be more profound in TTF group). Wong, E., Lok, E., Gautam, S., Swanson, K. (2015). Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma British Journal of Cancer 113(2), 232-41. https://dx.doi.org/10.1038/bjc.2015.238 A combination of 3 retrospective human patient cohorts and a mouse model of GBM looking at the correlation of Decadron with survival after RT. Also compared VEGF inhibitor in mouse model.Found worsening mortality associated with Decadron in all 3 cohorts using a multivariate model. In mouse model, Decadron made radiation therapy ineffective. VEGF inhibitors were able to control edema without worsening outcome. Pitter, K., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S., Donnola, S., Dai, C., Ozawa, T., Chang, M., Chan, T., Beal, K., Bishop, A., Barker, C., Jones, T., Hentschel, B., Gorlia, T., Schlegel, U., Stupp, R., Weller, M., Holland, E., Hambardzumyan, D. (2016). Corticosteroids compromise survival in glioblastoma Brain 139(5), 1458-1471. https://dx.doi.org/10.1093/brain/aww046 First reference in the literature I could find to this effect.Tested the effects of adding dex to human glioma cell cultures, treated with vincristine, cytarabine, methotrexate (MTX), and adriamycin. Found that decadron attenuated the effect of all tested chemo agents. Weller, M., Schmidt, C., Roth, W., Dichgans, J. (1997). Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone? Neurology 48(6), 1704-1709. https://dx.doi.org/10.1212/wnl.48.6.1704 Developed findings from Weller (1997) to look at mechanisms. Demonstrated that dDcadron inhibits apoptosis in human astrocytoma cells in culture. Gorman, A., Hirt, U., Orrenius, S., Ceccatelli, S. (2000). Dexamethasone pre-treatment interferes with apoptotic death in glioma cells Neuroscience 96(2), 417-425. https://dx.doi.org/10.1016/s0306-4522(99)00565-5 Phase II trial testing ipilimumab for brain melanoma mets. Included two cohorts: Cohort A - asymptomatic, Cohort B - symptomatic, taking Decadron. Cohort B survived longer. Was this due to worse disease, or the Decadron treatment? Margolin, K., Ernstoff, M., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J., Clark, J., Sznol, M., Logan, T., Richards, J., Michener, T., Balogh, A., Heller, K., Hodi, F. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial The Lancet Oncology 13(5), 459-465. https://dx.doi.org/10.1016/s1470-2045(12)70090-6

Immunotherapy – treating a disease by inducing, enhancing, or suppressing an immune response – remains one of the biggest hopes in terms of potentially finding a breast cancer cure. And yet, it also remains an incredibly challenging discipline. What works for one type of cancer may not for another. Why is that? What lessons can researchers take from successful cases – melanoma, lung or other cancers – and apply to breast cancer? And where, exactly, are researchers in finding an immunology answer for breast cancer?To find out, I spoke with one the nation’s leading researchers in the field, Dr. Jedd Wolchok. Dr. Wolchok is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center. A BCRF Investigator since 2011, he has helped establish the center as a leader in the discovery and treatment of cancers with novel immunotherapies. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials. He’s also, as I learned, proficient with the tuba. I confess – I didn’t see that one coming.

Dr Wolchok talks to ecancertv at ASCO 2015 about results from a randomised phase III trial which indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone. These results represent yet another major step forward in tackling melanoma.

Dr Wolchok presents, at a press conference at ASCO 2015, findings from a randomised phase III trial indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.

By releasing the brakes tumor cells place on the immune system, researchers develop new treatments for cancer. By Jedd D. Wolchok

By releasing the brakes tumor cells place on the immune system, researchers develop new treatments for cancer. By Jedd D. Wolchok

Prof Jedd Wolchok talks to ecancer at the 2013 ASCO Annual Meeting about a phase I study that involved the drug combination ipilimumab and nivolumab in melanoma. In cases of melanoma, ipilimumab impacts overall survival and nivolumab provides durable responses. Prof Wolchok explains the design of the trials and how using these drugs in combination target the PD1 trigger.

Interview with Jedd D Wolchok, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Jedd D Wolchok, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.